Skip to Main content Skip to Navigation
Journal articles

Programmed Death–Ligand 1 and Vimentin: A Tandem Marker as Prognostic Factor in NSCLC

Abstract : In non-metastatic non-small-cell lung cancer (NSCLC), outcomes remain poor. Adjuvant chemotherapies provide a limited improvement in disease-free survival. Recent exploratory studies on early-stage NSCLC show that immunotherapy given according to Programmed Death-Ligand 1 expression generates variable results, emphasizing a need to improve tumor characterization. We aimed to conjointly assess NSCLC, the expression of PD-L1, and epithelial-mesenchymal transition, frequently involved in tumor aggressiveness. 188 resected NSCLCs were analyzed. Among 188 patients with curatively resected NSCLC, 127 adenocarcinomas and 61 squamous cell carcinomas were stained for PD-L1 and vimentin expression. Overall survival has been compared regarding PD-L1 and vimentin statuses both separately and conjointly in Tumor Cancer Genome Atlas databases. PD-L1 and vimentin higher expressions were strongly associated (OR = 4.682, p < 0.0001). This co-expression occurred preferentially in tumors with lymph node invasion (p = 0.033). PD-L1 was significantly associated with high EMT features. NSCLC harboring both PD-L1 high /vimentin high expressions were significantly associated with poor overall survival (p = 0.019). A higher co-expression of vimentin and PD-L1 was able to identify patients with worse outcomes. Similar to an important prognostic marker in NSCLC, this tandem marker needs to be further presented to anti-PD-L1 immunotherapies to improve outcome.
Document type :
Journal articles
Complete list of metadata

Cited literature [46 references]  Display  Hide  Download
Contributor : Valerian Dormoy Connect in order to contact the contributor
Submitted on : Monday, May 11, 2020 - 4:10:01 PM
Last modification on : Wednesday, November 3, 2021 - 7:36:55 AM


Publisher files allowed on an open archive




Julien Ancel, Philippe Birembaut, Maxime Dewolf, Anne Durlach, Béatrice Nawrocki-Raby, et al.. Programmed Death–Ligand 1 and Vimentin: A Tandem Marker as Prognostic Factor in NSCLC. Cancers, MDPI, 2019, 11 (10), pp.1411. ⟨10.3390/cancers11101411⟩. ⟨hal-02448652⟩



Record views


Files downloads